HRP20211661T1 - Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti - Google Patents
Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti Download PDFInfo
- Publication number
- HRP20211661T1 HRP20211661T1 HRP20211661TT HRP20211661T HRP20211661T1 HR P20211661 T1 HRP20211661 T1 HR P20211661T1 HR P20211661T T HRP20211661T T HR P20211661TT HR P20211661 T HRP20211661 T HR P20211661T HR P20211661 T1 HRP20211661 T1 HR P20211661T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- amount
- igmesine
- inhibitor
- accordance
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims 7
- VCZSWYIFCKGTJI-JLHYYAGUSA-N igmesine Chemical compound C1CC1CN(C)C(C=1C=CC=CC=1)(CC)C\C=C\C1=CC=CC=C1 VCZSWYIFCKGTJI-JLHYYAGUSA-N 0.000 title claims 5
- 229950004066 igmesine Drugs 0.000 title claims 5
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 8
- 239000008186 active pharmaceutical agent Substances 0.000 claims 6
- SCHQQPAJNUHKSV-RSGUCCNWSA-N (e)-n-(cyclopropylmethyl)-n-methyl-3,6-diphenylhex-5-en-3-amine;hydrochloride Chemical compound Cl.C1CC1CN(C)C(C=1C=CC=CC=1)(CC)C\C=C\C1=CC=CC=C1 SCHQQPAJNUHKSV-RSGUCCNWSA-N 0.000 claims 5
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 4
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 4
- 229960005370 atorvastatin Drugs 0.000 claims 4
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 4
- 229960003530 donepezil Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 4
- 229960003946 selegiline Drugs 0.000 claims 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 3
- 239000003524 antilipemic agent Substances 0.000 claims 3
- 229960001680 ibuprofen Drugs 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 230000006974 Aβ toxicity Effects 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 230000006933 amyloid-beta aggregation Effects 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims 1
- 229960000245 rasagiline Drugs 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 229960003741 tranylcypromine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (16)
1. Farmaceutski pripravak, naznačen time što sadrži igmezin, ili njegovu farmaceutski prihvatljivu sol, namijenjen upotrebi u postupku liječenja Alzheimerove bolesti kod ljudskog subjekta kojem je to potrebno, gdje se postupak sastoji u primjeni igmezina kao monoterapije u rasponu od 1 do 20 mg dnevno.
2. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se igmezin primijenjuje u rasponu od 1 do 10 mg dnevno, izborno od 1 do 5 mg dnevno.
3. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je farmaceutski prihvatljiva sol hidrokloridna sol.
4. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je subjekt kojem je to potrebno ljudski pacijent s dijagnozom Alzheimerove bolesti.
5. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je pripravak prilagođen za doziranje jednom dnevno.
6. Farmaceutski pripravak, naznačen time što sadrži igmezin, ili njegovu farmaceutski prihvatljivu sol, namijenjen upotrebi u postupku liječenja Alzheimerove bolesti kod ljudskog subjekta kojem je to potrebno, gdje se postupak sastoji u primjeni igmezina u rasponu od 1 do 20 mg dnevno, te gdje postupak dodatno uključuje primjena najmanje jednog dodatnog aktivnog farmaceutskog sastojka ("API"), gdje se najmanje jedan dodatni API bira iz skupine koju čine inhibitor kolinesteraze, sredstvo za snižavanje toksičnosti Aβ, sredstvo za zamjenu hormona, sredstvo za snižavanje razine lipida, sredstvo za moduliranje sekretaze, inhibitor agregacije Aβ, inhibitor neurofibrilacije, protuupalno sredstvo, inhibitor monoamin-oksidaze, inhibitor katabolizma β-amiloida, te njihove kombinacije.
7. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je najmanje jedan dodatni API
a) inhibitor kolinesteraze, gdje inhibitor kolinesteraze može biti donepezil, te gdje uz to donepezil može biti prisutan u količini od 1 do 15 mg, od 1 do 10 mg, ili od 1 do 5 mg,
b) protuupalno sredstvo, po mogućnosti nesteroidno protuupalno sredstvo, gdje nesteroidno protuupalno sredstvo može biti ibuprofen, te gdje uz to ibuprofen može biti prisutan u količini od 50 do 150 mg,
c) inhibitor monoamin-oksidaze, izborno gdje inhibitor monoamin-oksidaze se bira između rasagilina, selegilina ili tranilcipromina, gdje uz to inhibitor monoamin-oksidaze B može biti selegilin, te gdje selegilin još može biti prisutan u količini od 5 do 15 mg, ili
d) sredstvo za snižavanje razine lipida, po mogućnosti statin, gdje se statin može birati između simvastatina ili atorvastatina, gdje uz to sredstvo za snižavanje razine lipida može biti atorvastatin, te gdje atorvastatin još može biti prisutan u količini od 1 do 5 mg.
8. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 6 ili 7, naznačen time što su igmezin i najmanje jedan dodatni API u odvojenim oblicima doziranja.
9. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je pripravak oralni oblik doziranja.
10. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 6 do 10, naznačen time što pripravak sadrži igmezin-hidroklorid u količini od 1 do 10 mg, po mogućnosti od 1 do 5 mg, a najmanje jedan dodatni API je inhibitor kolinesteraze.
11. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što se postupak sastoji u inhibiranju upale živčanog tkiva kod Alzheimerove bolesti.
12. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što je Alzheimerova bolest Alzheimerova bolest s ranim početkom.
13. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što pripravak sadrži igmezin-hidroklorid u količini od 2,5 do 10 mg po dozi, gdje se pripravak primjenjuje jedan, dva ili tri puta dnevno, na ljudskom subjektu.
14. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što sadrži igmezin-hidroklorid u količini od 2,5 do 10 mg po dozi, gdje se pripravak primjenjuje jedan, dva ili tri puta dnevno, na ljudskom subjektu, gdje pripravak dodatno sadrži:
a) donepezil u količini od 1 do 15 mg,
b) ibuprofen u količini od 50 do 150 mg,
c) selegilin u količini od 5 do 15 mg, ili
d) atorvastatin u količini od 1 do 5 mg.
15. Oblik jedinice doziranja, naznačen time što sadrži 1 do 20 mg igmezin-hidroklorida i 1 do 6 mg donepezila.
16. Oblik jedinice doziranja u skladu s patentnim zahtjevom 15, naznačen time što sadrži od 1 do 10 mg ili od 1 do 5 mg igmezin-hidroklorida.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662293832P | 2016-02-11 | 2016-02-11 | |
| EP17704271.0A EP3413870B1 (en) | 2016-02-11 | 2017-02-10 | Igmesine for use in the treatment of alzheimer's disease |
| PCT/EP2017/053066 WO2017137600A1 (en) | 2016-02-11 | 2017-02-10 | Igmesine for use in the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211661T1 true HRP20211661T1 (hr) | 2022-02-18 |
Family
ID=58009847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211661TT HRP20211661T1 (hr) | 2016-02-11 | 2017-02-10 | Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11129801B2 (hr) |
| EP (2) | EP3413870B1 (hr) |
| JP (1) | JP7059192B2 (hr) |
| CN (1) | CN109069414B (hr) |
| AU (1) | AU2017218592B2 (hr) |
| CA (1) | CA3012415C (hr) |
| CY (1) | CY1124821T1 (hr) |
| DK (1) | DK3413870T3 (hr) |
| ES (1) | ES2895957T3 (hr) |
| HR (1) | HRP20211661T1 (hr) |
| HU (1) | HUE056265T2 (hr) |
| LT (1) | LT3413870T (hr) |
| PL (1) | PL3413870T3 (hr) |
| PT (1) | PT3413870T (hr) |
| RS (1) | RS62615B1 (hr) |
| SI (1) | SI3413870T1 (hr) |
| WO (1) | WO2017137600A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3413870T (pt) | 2016-02-11 | 2021-09-10 | Sigmathera Sas | Igmesina para utilização no tratamento de doença de alzheimer |
| CA3230908A1 (en) * | 2021-09-20 | 2023-03-23 | Jose-Miguel Vela-Hernandez | Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4607824A (en) | 1983-01-11 | 1986-08-26 | Energy Absorption Systems, Inc. | Guardrail end terminal |
| FR2636625B1 (fr) * | 1988-09-01 | 1990-11-09 | Jouveinal Sa | Benzylamines disubstituees, leur procede de preparation, leur utilisation comme medicament et leurs intermediaires de synthese |
| NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| JP4600610B2 (ja) * | 1996-05-15 | 2010-12-15 | 株式会社フジモト・コーポレーション | アセチルコリン系神経伝達改善剤 |
| WO2000041684A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | A pharmaceutical combination for the treatment of depression |
| EP1078630A1 (en) | 1999-08-27 | 2001-02-28 | Warner-Lambert Company | Use of sigma receptor agonists for the treatment of depression |
| US6436938B1 (en) | 2001-01-22 | 2002-08-20 | Pfizer Inc. | Combination treatment for depression |
| PT1392287E (pt) | 2001-05-25 | 2007-02-28 | Schering Corp | Métodos para tratamento de doença de alzheimer e/ou regulação dos níveis de peptídeos β amilóide num sujeito |
| WO2005000294A1 (en) | 2003-06-06 | 2005-01-06 | Pharmacia Corporation | Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
| WO2004110388A2 (en) * | 2003-06-12 | 2004-12-23 | Agy Therapeutics, Inc. | Sigma ligands for neuronal regeneration and functional recovery |
| CN100420483C (zh) * | 2003-06-12 | 2008-09-24 | 株式会社爱慕知科学 | 用于神经元再生和功能恢复的σ配体 |
| JP2007532624A (ja) * | 2004-04-14 | 2007-11-15 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アルツハイマー病の治療のための療法組合せ |
| US20070123556A1 (en) | 2005-06-06 | 2007-05-31 | University Of South Florida | Treatment with Sigma Receptor Agonists Post-Stroke |
| FR2970869B1 (fr) * | 2011-01-31 | 2013-09-06 | Centre Nat Rech Scient | Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel |
| WO2016138135A1 (en) * | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| PT3413870T (pt) | 2016-02-11 | 2021-09-10 | Sigmathera Sas | Igmesina para utilização no tratamento de doença de alzheimer |
-
2017
- 2017-02-10 PT PT177042710T patent/PT3413870T/pt unknown
- 2017-02-10 SI SI201730963T patent/SI3413870T1/sl unknown
- 2017-02-10 CN CN201780021077.9A patent/CN109069414B/zh active Active
- 2017-02-10 EP EP17704271.0A patent/EP3413870B1/en active Active
- 2017-02-10 ES ES17704271T patent/ES2895957T3/es active Active
- 2017-02-10 RS RS20211350A patent/RS62615B1/sr unknown
- 2017-02-10 AU AU2017218592A patent/AU2017218592B2/en active Active
- 2017-02-10 PL PL17704271T patent/PL3413870T3/pl unknown
- 2017-02-10 WO PCT/EP2017/053066 patent/WO2017137600A1/en active Application Filing
- 2017-02-10 HU HUE17704271A patent/HUE056265T2/hu unknown
- 2017-02-10 LT LTEPPCT/EP2017/053066T patent/LT3413870T/lt unknown
- 2017-02-10 DK DK17704271.0T patent/DK3413870T3/da active
- 2017-02-10 US US16/076,504 patent/US11129801B2/en active Active
- 2017-02-10 HR HRP20211661TT patent/HRP20211661T1/hr unknown
- 2017-02-10 EP EP21181531.1A patent/EP3903767A1/en active Pending
- 2017-02-10 CA CA3012415A patent/CA3012415C/en active Active
- 2017-02-10 JP JP2018543150A patent/JP7059192B2/ja active Active
-
2021
- 2021-10-26 CY CY20211100929T patent/CY1124821T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3012415A1 (en) | 2017-08-17 |
| PT3413870T (pt) | 2021-09-10 |
| CA3012415C (en) | 2024-03-12 |
| SI3413870T1 (sl) | 2021-12-31 |
| CN109069414A (zh) | 2018-12-21 |
| CY1124821T1 (el) | 2022-11-25 |
| US11129801B2 (en) | 2021-09-28 |
| WO2017137600A1 (en) | 2017-08-17 |
| EP3413870A1 (en) | 2018-12-19 |
| LT3413870T (lt) | 2021-11-10 |
| US20190046472A1 (en) | 2019-02-14 |
| AU2017218592A1 (en) | 2018-08-09 |
| EP3903767A1 (en) | 2021-11-03 |
| EP3413870B1 (en) | 2021-08-04 |
| PL3413870T3 (pl) | 2022-01-10 |
| CN109069414B (zh) | 2022-01-14 |
| AU2017218592B2 (en) | 2022-10-20 |
| JP7059192B2 (ja) | 2022-04-25 |
| DK3413870T3 (da) | 2021-11-01 |
| HUE056265T2 (hu) | 2022-02-28 |
| ES2895957T3 (es) | 2022-02-23 |
| RS62615B1 (sr) | 2021-12-31 |
| JP2019504872A (ja) | 2019-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200600T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2015038135A5 (hr) | ||
| HRP20130057T1 (hr) | Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom | |
| JP2017506624A5 (hr) | ||
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| HRP20230272T1 (hr) | Postupci za liječenje cistične fibroze | |
| WO2008027350A3 (en) | Acetaminophen pharmaceutical compositions | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| JP2013541583A5 (hr) | ||
| JP2016505050A5 (hr) | ||
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| HRP20211661T1 (hr) | Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti | |
| JP2011500589A5 (hr) | ||
| JP2019513814A5 (hr) | ||
| JP2005519936A5 (hr) | ||
| HRP20230735T1 (hr) | Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta | |
| HRP20230693T1 (hr) | Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| JP2015515971A5 (hr) | ||
| IL275091B1 (en) | Methods for treating Gaucher's disease | |
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
| JP2019524782A5 (hr) | ||
| RU2020108631A (ru) | Новая вспомогательная терапия для применения в способе лечения рака простаты |